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Abstract
Additional chromosomal abnormalities are currently detected in Burkitt’s lymphoma. They play major roles in the
progression of BL and in prognosis. The genes involved remain elusive. A whole-genome oligonucleotide array CGH analysis
correlated with karyotype and FISH was performed in a set of 27 Burkitt’s lymphoma-derived cell lines and primary tumors.
More than half of the 145 CNAs,2 Mb were mapped to Mendelian CNVs, including GSTT1, glutathione s-transferase and
BIRC6, an anti-apoptotic protein, possibly predisposing to some cancers. Somatic cell line-specific CNVs localized to the IG
locus were consistently observed with the 244 K aCGH platform. Among 136 CNAs .2 Mb, gains were found in 1q (12/27),
13q (7/27), 7q (6/27), 8q(4/27), 2p (3/27), 11q (2/27) and 15q (2/27). Losses were found in 3p (5/27), 4p (4/27), 4q (4/27), 9p
(4/27), 13q (4/27), 6p (3/27), 17p (3/27), 6q (2/27),11pterp13 (2/27) and 14q12q21.3 (2/27). Twenty one minimal critical
regions (MCR), (range 0.04–71.36 Mb), were delineated in tumors and cell lines. Three MCRs were localized to 1q. The
proximal one was mapped to 1q21.1q25.2 with a 6.3 Mb amplicon (1q21.1q21.3) harboring BCA2 and PIAS3. In the other 2
MCRs, 1q32.1 and 1q44, MDM4 and AKT3 appeared as possible drivers of these gains respectively. The 13q31.3q32.1
,89.58–96.81. MCR contained an amplicon and ABCC4 might be the driver of this amplicon. The 40 Kb 2p16.1 ,60.96–
61. MCR was the smallest gained MCR and specifically encompassed the REL oncogene which is already implicated in B cell
lymphomas. The most frequently deleted MCR was 3p14.1 ,60.43–60.53. that removed the fifth exon of FHIT. Further
investigations which combined gene expression and functional studies are essential to understand the lymphomagenesis
mechanism and for the development of more effective, targeted therapeutic strategies.
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Introduction
First described by D. Burkitt in 1958, Burkitt’s lymphoma (BL)
is a monoclonal proliferation of malignant B lymphocytes. It is a
mature aggressive lymphoma that accounts for 30 to 50% of
lymphomas in children and for 1 to 2% in adults [1]. Its original
description, a jaw tumor, led to the discovery of Epstein-Barr virus
(EBV). Because of its high frequency in children living in the
African equatorial regions (the Burkitt Belt), heavily infected by
EBV and malaria [2] this viral linked tumor was qualified of
endemic. It was identical, by morphology (cytology and pathol-
ogy), immunophenotype and chromosome abnormalities to
mature aggressive lymphomas, mainly EBV negative, that were
observed in all the world. This type of BL, coined as sporadic,
accounts for 30 to 50% of lymphomas in children and for 1 to 2%
in adults [1]. The treatment of endemic and sporadic BL rely on
high dose of chemotherapy with good results in children.
The hallmark of this disease is the t(8;14) translocation or one of
the variant t(8;22) or t(2;8) translocations, associating the MYC
gene (located at 8q24) to one of three immunoglobulin loci [3,4].
These balanced chromosomal translocations result in constitutive-
ly deregulated MYC expression by position effect, whatever the
break point location and the transcription orientation [5],
Hypothesized as a transforming factor located on 8q24, MYC
was the first oncogene isolated in a human malignancy,
responsible for maintaining the balance of cellular proliferation,
differentiation, adhesion and apoptosis.
By virtue of the translocation, MYC is in the position of the
variable part of Ig genes [5] that is subjected to hypermutation by
the AID activation [6].
Additional chromosomal abnormalities, detected in 70% of
pediatric BL, seem to be important factors influencing clinical
outcome [7,8]. Gain of 7q and del(13q) seems strong genetic
indicators of a poor prognosis [9]. Although many of these
chromosomal anomalies undoubtedly play major roles in the
pathogenesis of BL, the genes involved have remained elusive.
High resolution CGH array (aCGH) [10,11] is a powerful
method to identify pathogenic DNA copy-number changes (gain,
amplification and deletion) on a genome-wide scale, and to map
these changes to genomic sequence. It does not detect balanced
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isolation of genomic DNA isolated from test and reference cell
populations, differential labeling with fluorescent dyes and
cohybridization with a high-resolution DNA microarrays. Oligo-
nucleotide CGH arrays enable genome-wide detection of DNA
copy-number changes down to 15,20 Kb.
Recurrent chromosomal rearrangements in various tumors
define Minimal Critical Regions (MCR) that are often small
enough to pinpoint the few candidate genes in oncogenesis that lie
in this chromosomal region. Many of these MCR contain known
oncogenes and tumor suppressor genes and also help identify new
genes that are critical in lymphomagenesis.
In this study, whole-genome 44K and 244K oligonucleotide
arrays were used for fine mapping of recurrent copy number
alterations (CNA) present in a set of 27 human Burkitt’s
lymphomas. These results allow a global view of genomic
instability at a high level resolution (50 Kb on average) and the
identification of new gene loci that are recurrently altered.
Materials and Methods
Primary Tumors and Cell Lines
The patients were studied according to various protocols
approved by the French Ethics Committees. Between 1995 and
2005, 13 BL tumors were collected and frozen at disease onset.
Tumor specimens were reviewed by an expert hematopathologist
according to current WHO criteria for morphologic, immuno-
phenotypic, and cytogenetic features.
Fifteen Burkitt’s lymphoma-derived B cell lines were studied:
BL2, BL31, BL41, BL70, BL84, BL104, BLLAL, Ly47, Ly91,
Namalwa, Ramos, Oku, Salina, Seraphina and BLMer (derived
from the relapse of tumor case 29124, thus counting one BL for
both samples). They were cultured at 37uC in complete medium
(GIBCO-BRL, Scotland) containing 2 mM L-glutamine, 1 mM
pyruvate, 20 mM glucose, 20 mg/ml gentamicine and supple-
mented with 5% heat-inactivated fetal calf serum.
Ethics Statement
No ethics statements are required for this work.
Cytogenetic analysis
Cytogenetic analysis was performed on metaphase spreads obtained
f r o mt u m o rb i o p s yo rb o n em a r r o ws p e c i m e n sa n dc e l ll i n e s .I ne a c h
case, 15 RHG-banded metaphases were analyzed when possible.
Clonal chromosomal abnormalities were described according to the
International System for Human Cytogenetic Nomenclature [12].
Fluorescence in situ hybridization (FISH) studies
A set of commercial probes was used to diagnosis in some cases
and to resolve discrepancies between aCGH results and karyotype
data (Supplementary Table S1). To confirm DNA copy number
changes obtained from aCGH, a FISH analysis was carried out
using individual probes on cytogenetic preparations. Five BAC
clones (Table S1) were selected from Pieter De Jong libraries
(http://www.chori.org/bacpac/) according to their position on
the UCSC human genome (http://www.genome.ucsc.edu/).
Purified BAC DNA was labeled by random priming in the
presence of Alexa 488-dUTP (green) and Alexa 594-dUTP (red)
(Abbott). The quality of the probes was verified by hybridization to
metaphase spreads of a negative control. The preparations were
observed with an epifluorescence microscope and images captured
with a Vysis imaging station. Between 20 and 40 metaphase
spreads and 100 nuclei were analyzed for each sample.
Oligonucleotide aCGH
Tumor genomic DNA was isolated according to Qiagen
protocols with modifications [13]. Samples containing a t(8;V)
were detected by cytogenetic analysis and/or FISH (dissociation of
the MYC signal) in more than 60% of cells. High-molecular-
weight genomic DNA was extracted from the cell lines with a
DNeasy extraction kit (Qiagen).
Patient tumor samples and cell lines were analyzed using 44K
and 244K microarrays (Agilent Technologies, Santa Clara, CA,
USA) respectively. Only cell lines were processed as dye-swap pairs.
In all experiments, sex-matched DNA from a pooled human female
or male individual (Promega, Madison, WI) was used as the
reference. Oligonucleotide aCGH processing was performed as
detailed in the manufacturer’s protocol (version 4.0; http://www.
agilent.com). Data were extracted from scanned images using
feature extraction software (version A.8.5.3, Agilent). Raw data text
files from the latter were then imported for analysis into CGH
Analytics 3.4.40. Aberrations were detected with the ADM2
algorithm and filtering options of a minimum of 5 probes and
abs(log2Ratio) .0.3. Aberration segments were individually
reviewed using build 35, hg17 of UCSC [14]. Anomalies that were
localized to regions with high-copy repetitive or GC-rich DNA
sequences including telomeric regions were excluded. We defined
gains and losses for the oligonucleotide dataset as a linear ratio $1.2
or #0.8 respectively. High and low-level amplification events were
defined as a linear ratio $4o r2 , ratio ,4 respectively. The data
aredescribedin accordancewith MIAMEguidelines and have been
deposited in ArrayExpress under E-TABM-703 accession number.
Results
Cytogenetic results
The karyotype of the primary tumor was complex in 4 cases
(Table 1).
Among the 15 cell lines, 13 exhibited a complex karyotype
(Table 2); 11 harbored the same chromosomal abnormalities that
were previously described [15,16], while BLLAL, BLMER, OKU
and Salina have not been reported elsewhere. The hallmark t(8;14)
translocation was detected in 18 tumors or cell lines. The variant
t(8;22) translocations were found in 1 tumor and 5 cell lines and
the t(2;8) were found in 2 tumors and 1 cell line.
aCGH CNA correlate with conventional and molecular
cytogenetic results. A strong correlation between aCGH results
and karyotype analysis was observed for CNA $5 Mb. Some larger
CNA were detected in cell lines exclusively by aCGH. For example,
in the Ly47 cell line, a gain of a 25.75 Mb region on 16q21qter
,62.92–88.67. could not be detected by karyotype analysis (Fig. 1
A+B). This gain was confirmed by FISH (Fig. 1C). In the Ly91 cell
line, a nonsegmented gain of 1q was observed on aCGH (Fig. 1E)
that allowed FISH to identify a der(13)t(1;13)(q32.1;p12) present in
only 20% of the cells (Fig. 1 D+F). Often aCGH refined the
breakpoints detected by conventional cytogenetics. In addition to
primary BL translocations, four other balanced translocations were
only shown by karyotype analysis without any visible scar at 20 Kb
resolution (Table 2).
Analysis of small-scale copy number alteration: CNVs
Small sized CNA (n=145) defined as #2 Mb long, ranging from
0.03 to 2 Mb in size, were detected in 140 occurrences originating
from 244 K arrays, and 5 from 44 K. More than half of these small
CNA were found to be Mendelian CNVs. This was tested by
examining the sequence present at each CNA, with the University
of California at Santa Cruz Genome Browser (http://genome.cse.
ucsc.edu) and Toronto (http://projects.tcag.ca/variation) tools.
Burkitt aCGH Analysis
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Tumors Age (years)/Sex CNA Coordinates (Mb) Cytogenomic karyotype
28787 4/F 22p23.1p16.3 ,31.32–49.17. 46,XX,der(3)t(3;?)(q2;?),t(8;14)(q24.2;q32.3)[15]
23q26.3q27.1# ,183.94–185.30.
+7q21.1qter ,87.24–158.6.
212q21.3# ,79.246–80.19.
29123 8/M +1q21.1q25.3 ,143.72–182.28. 47,XY,dup(1)(q21q25),t(8;14)(q24.2;q32.3),
213q21.1q21.2 ,52.77–57.69. del(17)(p11),+ mar[15]
+13q21.3q33.1 ,69.49–103.22.
213q33.1q34 ,103.63–109.46.
217pterq11.1 ,0.04–22.33.
29124 32/M no statistically significant CNA 46,XY,t(8;14)(q24.2;q32.3)[150]
29125 68/F 21p31.1p12 ,71.21–119.36. 47,49,XX,del(1)(p13p31),t(2;8)(p11.2;q24.2),
+1q21.1q32.1 ,148.08–205.17 der(3)t(3;?)(q27;?),29,+ add(11)(p15),+ mars[15]
23q28qter ,190.07–194.87.
24p16.1p14 ,10.88–37.52.
24q32.1qter ,161.36–191.12.
29pterp13.3 ,0.32–33.06.
29q12q34.1 ,66.22–129.48.
211pterp13 ,3.3–32.41.
+11q22.1qter ,101.45–133.95.
213q14.1q14.3 ,40.4–51.07.
29127 9/M no statistically significant CNA ish t(8;14)(q24.2;q32.3)(wcp8+,wcp14+; wcp14+,wcp8+)
29139 82/M 21p36.3p35.3 ,3.64–29.63. 47,XY,der(3)del(3)(p?)t(3;?)(?;?),t(8;14)
23pterp11.1 ,0.22–90.26. (q24.2;q32.3.3),+mar[15]
+3q11.2qter ,95.29–199.28.
26q13q22.1 ,75.21–114.87.
29p21.3[x0.25] # ,21.73–22.31.
+10pterp14 ,0.13–9.39.
211q13.5qter ,75.18–133.72.
213q12.1q14.1 ,20.35–42.57.
213q21.2q31.3 ,59.28–93.42.
213q32.3qter ,99.06–112.61.
214q12q21.3 ,26.52–43.84.
+18q11.1qter ,16.9–76.08.
29140 12/M no statistically significant CNA 46,XY,t(8;22)(q24.2;q11.2)[15]
29141 41/M +1q21.1q25.3 ,144.28–181.75. 46,XY,t(8;14)(q24.2;q32.3),der(13)t(1;13)(?;?)[15]
213q31.1q31.2 ,84.36–86.95.
213q33.1qter ,103.63–114.07.
29142 61/F no statistically significant CNA 46,XX,t(8;14)(q24.2;q32.3)[15]/idem,del(4)(q24q31)[4]
29143 62/M no statistically significant CNA 46,XY,t(8;14)(q24.2;q32.3)[15]
29145 57/M +1q21.1q25.3 ,143.72–178.73. 46,XY,dup(1)(q21q25),der(14)t(8;14)(q24.2;q32.3)[15]
+8q24.2qter ,128.81–146.25.
211q24.1qter ,120.99–133.76.
29146 55/M no statistically significant CNA 46,XY,t(8;14)(q24.2;q32.3)[15]
29147 15/M +2p16.1# ,60.96–61. 46,XY,t(2;8)(p11.2;q24.2),add(13)(q?)[15]
+8p23.1# ,10.1–11.
+13q31.3q32.3 ,89.58–99.61.
213q32.3qter ,99.87–114.07.
Results from chromosomal banding are in plain characters and # indicate small size CNAs.
doi:10.1371/journal.pone.0007089.t001
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Cell Lines CNA Coordinates (Mb) Cytogenomic karyotype
BL2 +1q21.1q31.3 ,142.11–193.88. 46,XY,der(1)dup(1)(q21.1q31.3)dic(1;7)(q31.3;q10),
26q24.1qter ,142.01–170.82. dic(1;6)(q10;q24.1),t(8;22)(q24.2;q11.2),
+ 7q11.2qter ,61.47–158.57. del(10)(p12.1),der(13;13)(q10;q10)[15]
29p21.3[x0,05]
# ,21.89–22.54.
210pterp12.1 ,0.11–38.66.
+13
215q14
# ,34.61–35.52.
BL31 +1q21.1q31.1 ,142.56–184.06. 46,XY,dup(1)(q21.1q31.1),t(8;14)(q24.2;q32.3),
210p14p11.2 ,11.25–36.95. del(10)(p14p11.2),der(13)del(13)(q13.1q31.2)
213q13.1q31.2 ,32.35–87.94. dup(13)(q31.2qter)[15]
+13q31.2qter ,88.01–112.92.
BL41
$ +1q12q21.1 ,141.46–142.87.[x2.6] 84,89,XXYY,dup(1)(p36.1p35.1),dup(1)(q12q25.3),
+1q21.1 ,142.87–143.28.[x3.8] del(2)(p16.3q36.3),del(3)(q13.1q21.3)x2,24,
+1q21.1q25.3 ,143.28–180.03.[x2.6] der(4)(4pter-.q32.2::?-.?::-.4q35.1-.4qter),
+1q32.1
# ,200.97–201.36. del(6)(6p12.3q12),+7x2,28,
+2p16.1p15 ,60.82–62.21.[x3] t(8;14)(q24.2;q31.3)x2,del(9)(p24.1q22.1),
+2p15p14 ,62,22–65,11.[x1,8] del(11)(p15.1q22.3),del(16)(p11.2q23.2),
22p12qter ,79,22–230,59.[x0,75] del(17)(p11.2)x2,dup(17)(q21.3qter),
23q13.1q21.3 ,106,02–131,82. del(18)(p11.31q22.3),+20,
23q26.3 ,176,02–178,83. der(22)t(11;22)(q22.3;q13.3),mar(s)[15]
24p16.2q13.3 ,4,92–71,26.[x0,75]
24q22.1q35.1 ,90,69–187,4.
25q33.1
# ,150,42–151,29.
25q33.2
# ,154,144–155,125.
26pterq12 ,0,1–67,66.[x0,75]
+7
28
29p24.1p21.1 ,7,5–32,13.[x0,75]
29p13.2q33.1 ,37,92–119,58.[x0,75]
211
+12p13.3
# ,5,88–7,27.
215q14
# ,33,47–33,5.
216
217pterp11.2 ,0,02–19,68.
+17p11.2
# ,19,69–21,44.
+17q21.3qter ,41,06–78,65.
218
+20
222q13.3qter ,44,82–49,5.
BL70 +1q21.2q25.2 ,146,81–176,59. 47,XY,dup(1)(q21.2q25.2),del(2)(q13q24.1),
22q13q24.1 ,110,18–156,88. +7,t(8;14)(q24.2;q32.3),t(12;22)(q12;q13)[15]
+7
BL84 +1 50,XY,+Y,+1,der(3)del(3)(p22.1p12.3)del(3)
23p22.1p12.3 ,41,97–76,58. (q26.2q28),+5,t(8;22)(q24.2;q11.2),+der(8)t(8;22)
23q26.2
# ,172,08–172,15. (q24.2;q11.2)[15]
23q26.3q28 ,184,06–191,84.
+5
+8pterq24.2 ,0,06–129,15.
+22q11.2q13.3 ,21,58–49,05.
+Y
Burkitt aCGH Analysis
PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e7089Cell Lines CNA Coordinates (Mb) Cytogenomic karyotype
BL104 24q13.2q21.1 ,67,38–77,21. 47,XX,t(1;3)(q24;p25),t(8;12)(p23;q24),
24q28.3q31.2* ,136,56–151,65. t(8;22)(q24.2;q11.2),+inv(12)(?p13q24.2)[8]/
24q34.1
# ,174,14–174,94. 47,XX,t(1;3),der(4)del(4)(q13.2q21.1)t(4;?)(q21.1;?),
24q34.3q35.1 ,182,3–186,69. der(4)del(4)(q28.3q35.1)t(4;?;12)(q35.1;?;?),
25p13.2
# ,36–37,44. t(8;22),der(9)del(9)(q21.3q31.1)t(4;9;12;?)(?;?q31;?;?)
29q21.3q31.1 ,79,24–100,39. ,der(12)t(5;12)(q13.2;?),+der(12)(4;5;12)(?;?;?) [7]
+12
BL LAL no statistically significant CNA 46,XY,t(8;14)(q24.2;q32.3),t(12;22)(q12;q11.2)[15]
BLMer 23p14.2
# ,60,28–60,64. 47,XY,t(5;22)(q12;q13),t(8;14)(q24.2;q32.3),
25q11.2q12.13
# ,58,88–59,12. +13,der(18)t(13;18)(q12.2;q21.2),
+13q12.2qter [x2] ,27,74–114,12. der(19)del(19)(q13.2qter)dup(19)(q13.1q13.2)[15]
218q21.2qter ,51,67–76,11.
+19q13.1q13.2 ,40,69–46,22.
219q13.2qter ,46,54–63,78.
Ly47 +1q43q44 ,236,62–245,43. 47,XY,+Y,dup(1)(q43q44),der(6)t(3;6)(6pter-.6q24.1:
23p14.2
# ,60,36–60,54. :3q26.3-.3qter),der(8)(8pter-.8q24.2::22q11.2.22q12.3
+3q26.3qter ,176,05–199,38. :8q21.2.-.8q24.2::22q11.2-.22qter),
26q24.1qter ,142,16–170,83. der(11)(11pter-.11q2?3::16q21-.16qter),
+8q21.2q24.2 ,86,91–129,16. del(14)(q31.3qter), der(18)(11q2?3::18p11-.18qter),
214q31.3qter ,88,09–106,34. der(22)t(8;22)(q24.2;q11.2)[15]
+16q21qter ,62,92–88,67.
+22q11.2q12.3 ,21,58–31,49.
+Y
LY91 no statistically significant CNA 46,XX,t(2;8)(p11.2;q24.2)[12]/46,XX,idem,
der(13)t(1;13)(q32.1;p12)[3]
Namalwa +1pterp36.1 ,1,74–18,8. 45X,?-Y,dup(1)(pterp36.1),dup(1)(q11q31.1),
+1q12q31.1 ,141,5–186,86. der(3)t(3;4)(3qter-.3p11.1::4p11-.4qter),
+1q44
# ,240,24–241,35. der(3)(3pter-.3q29::5q12.1-.5q23),-4,
23p25.1p11.1 ,15,3–90,39. der(5)(5pter-.5q12.1::5q23-.qter),
+3q26.1qter ,163,87–199,32. der(6)t(3;6)(3q26.3;6p22.2),+7, dup(9)(q34.1qter),
24pterp11 ,0,62–48,92. der(10)del(10)(q22.1q23.1)t(3;10)(q28;p24),
25q11.2q12.1 ,53,99–61,52. der(14)del(14)(q12q24)t(8;14)(q24.2;q32.3),
26pterp22.2 ,0,33–24,68. der(17)t(3;13;17)(3p?ter::17p12::hsr13q22-.q32:
+7 :17p11.2-.17qter),dup(18q21.1q21.3)[17]
+9q34.1qter ,127,34–138,34.
210q22.1q23.1 ,71,66–83,88.
+13q22.3q31.2 ,76,54–92,10.[x4]
+13q31.3q32.1 ,92,11–95,82.[x5,7]
214q12q24.3 ,31,73–75,3.
+17p12p11.2 ,15,47–21,1.
+18q21.1q21.3 ,44,13–55,48.
OKU +2pterq21.3 ,0,02–136,96. 46,XY,+del(2)(q21.3),-6,t(8;22)(q24.2;q11.2)[5]/
28pterp12 ,0,16–29,88. 47,XY,+del(2)(q21.3),
+10q22.1qter ,71,61–135,31. der(8)(22qter-.22q11.2::8q24.2.8p12::10q22.1.10qter),
+15q26.2qter ,92,15–100,21. der(8)t(8;15)(8qter-.8p2?3::15q26.2-.15qter)[11]
Ramos** 23p14.2
# ,60,43–60,53. 45,X,?-Y,del(3)(q12.3q21.3),inv(4)(p14q21),
23q12.3q21.3 ,102,69–129,51. del(6)(q22.3q23.2),t(8;14)(q24.2;q32.3),
+3q23qter ,143,27–199,32. der(16)t(7;16)(q11.2;p13), der(17)(17qter-.17p11.2:
25q31.2
# ,138,16–138,27. :hsr(13)(q14q31),
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PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e7089Eighty one of the 145 small CNA were mapped to Mendelian CNV
(mCNV) in the Database of Genomic Variants. Among these
mCNV, there were very frequent CNVs overlapping the large
group of olfactory receptor genes, the UGT2B17 and UGT2B28
genes. The genes encoding the HLA group were also detected
within these common CNVs. In our set, the GSTT1 gene exhibited
the most frequent CNVs. This locus was gained (5 copies) in 7 cases
and homozygously lost in three cases.
Immunoglobulin Somatic Copy Number Variation
Thirty-eight of the small CNA were mapped to the immuno-
globulin loci at chromosomal subbands 2p11.2 (IGK), 14q32.3
(IGH) and 22q11.2 (IGL) (Table S2, Figure 2, Figure S1, Figure
S2, Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure
S8, Figure S9, Figure S10, Figure S11). These acquired
monoclonal alterations were ascertained only by the 244 K
aCGH platform. The IGH locus was rearranged in all cell lines
(14/15 on the two chromosomes), with a specific pattern for each
cell line and it expressed surface IgM. In addition, IGK gene
rearrangements were also detected in all cell lines (8/15 biallelic).
IGK was homozygously rearranged in the only t(2;8). IGL locus
somatic rearrangements were observed in 10 cell lines (7 biallelic).
The other 5 cell lines, whose IGL locus was in germline
configuration, only exhibited surface IgK expression (Table S2).
In the t(8;22) the IGL gene was rearranged on the two alleles in 4
cases. The only hemizygote was observed in the OKU cell line
(Figure S8) which expressed IGK. These results, consistent with
the germinal center nature of BL cells, and the processes of
maturation of immunoglobulin, show a very good concordance
between immunophenotype and aCGH results.
Other Small Somatic Copy Number Alterations
Among the 26 remaining small-scale CNA (Tables 1 and 2), 16
imbalances were localized to either intergenic regions or predicted
gene sequences of unknown function. The significance of these
CNA remains to be determined. Ten imbalances were mapped to
regions containing characterized genes, many of which play roles
in tumorigenesis and B-cell differentiation and proliferation. These
genes allowed either the narrowing of the minimal critical regions
or remained as a single CNA (see below).
Cell Lines CNA Coordinates (Mb) Cytogenomic karyotype
26q22.3q23.2 ,121,26–134,4. der(18)(18pter-.18q21.3::18q12.1-.18q21.3:
+7q11.2qter ,72,27–158,61. :3q23-.3qter),+r [11]/44,idem,-r[4]
+11q23.1
# ,110,62–110,81.
213q12.1q14.1 ,25,14–39,85.
+13q14.1 ,40,25–45,19.
+13q21.3q31.1 ,70,41–85,36.
213q31.1q31.2 ,85,4–87,85.
+13q31.2q33.1 ,87,87–101,55.
213q33.1qter ,101,56–109,37.
217pterp11.2 ,0,02–20,58.
+18q12.1q21.3 ,27,21–53,62.
218q21.3qter ,52,65–76,11.
2Xq21.3 ,88,85–92,1.
Salina +1q21.2q31.3 ,146,66–192,35. 46,XX,dup(1)(q21.2q31.1),t(8;14)(q24.2;q32.3)[9]/
24p15.3p15.2 ,18,2–23,74. 46,sl,der(4)t(4;10)(q34.3;q23.3)[4]/
24q34.3q35.2 ,179,18–191,31. 46,Sdl1,der(4)t(4;?)(4p15.2;?)[2]
+10q23.3q24.3 ,96,97–105,61.
Se ´raphina +1q21.1qter ,142,57–245,43. 48,XX,der(2)t(1;2)
+2pterp24.3 ,0,02–14,02. (1qter-.1q21.1::2p25-.p24.3::2p25-.2qter),+4,
+4 der(6)t(6;?)(?::6p22.1-.6qter),t(8;14)(q24.2;q32.3),
25q33.3
# ,158,08–158,18. +15,dup(16)(q23.2qter),del(18)(p11.2)[15]
26p24.2p22.1 ,11,2–28,88.
+8q24.2
# ,128,71–128,95.
+15
218p11.3p11.2 ,0–15,11.
+16q23.2qter ,79,59–88,69.
220q11.2
# ,32,51–32,65.
*BL104 has a complex rearrangement on 4q.
**Ramos has a very complex rearrangement on 13q.
#indicate small size CNAs.
$In BL41, the 1q12q25.2 gain was segmented due to the presence of two amplicons.
Results from chromosomal banding are in plain characters, those from FISH (see supplementary data table 1) are in bold and those from aCGH are in italic.
doi:10.1371/journal.pone.0007089.t002
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The total number of CNA .2 Mb was 136 in cell lines and
tumors (Table 1). There were 17 whole chromosome gains or
losses and 119 structural CNA (sCNA). The distribution of these
sCNA was bimodal, with primary tumors or cell lines tending to
have either a large number or no large CNA. From the frequency
analysis, we observed the general trends of 1q (12/27), 13q (7/27),
7q (6/27), 8q (4/27), 2p (3/27), 11q (2/27) and 15q (2/27) gains
whereas losses were more frequent at the following chromosomal
regions: 3p (5/27), 4p (4/27), 4q (4/27), 9p (4/27), 13q(4/27), 6p
(3/27), 17p (3/27), 6q (2/27), 11pterp13 (2/27) and 14q12q21.3
(2/27).
Minimal critical region altered in BL
Some of these CNA were recurrent across different samples and
allowed us to define 21 MCRs of gain/amplification or loss/
deletion (Table 3). A nearly equal number of lost and gained MCR
were defined and their median size was 4.96 Mb (range 0.04–
71.36 Mb).
The most frequent gained region was 1q followed by 13q. Three
different MCRs weremappedto1q.The proximalonewasmapped
to 1q21.1q25.2. The BL 41 cell line exhibited a 6.3 Mb amplicon
localized at 1q21.1q21.3 ,142.87–149.17 Mb. (Fig. 3A+B+C).
The region exhibiting the highest copy number (as many as 7
copies), contained 14 genes and among them, BCA2 and PIAS3
seemed to be possible oncogenes. Two other MCRs were isolated
on 1q (Table 3). Three different MCRs were mapped to 13q
(Table 3). The most frequent one mapped to 13q31.3q32.1,
contained the Namalwa cell line amplicon (Fig. 3F). A 240 Kb
MCR at 8q24.2 encompassed MYC. A loss of 13q33.1q34 was only
found in tumors. In our set, the most frequent deleted region was
3p14.2 followed by 9p21.3 and a deletion of 17p (Table 3).
Discussion
In this work, we report a fine mapping of chromosomal imbalances
in a set of 27 BL primary tumors and cell lines. Whole-genome 44 K
and 244 K oligonucleotide arrays were used to analyze recurrent
copy number alterations present in tumors and cell lines respectively.
Comparison of the 15 dye-swap pairs from cell lines revealed
identical aberrations. In most cases, the boundaries of the chromo-
somal aberrations were absolutely identical. The dye-swap helped to
reduce the background level. Whole-genome oligonucleotide micro-
arrays aCGH analysis allowed us to delineate the chromosomal
imbalances at 15,20 Kb resolution in the 15 cell lines (244 K) and at
70 Kb average resolution in the 13 primary tumors (44 K).
Each sample was also investigated using conventional cytoge-
netics. Close agreement between karyotype data and whole-
genome aCGH CNAs wasobserved. When discrepanciesoccurred,
they were mostly explained, i) by a lack of detection due to
karyotype resolution; ii) by aCGH locally blurred heterogeneous
cell clones, or normal cell contamination in the sample; iii) by the
presence of balanced chromosomal rearrangements. In addition to
BL hallmark anomalies, 4 other apparently balanced translocations
were detected exclusively by conventional cytogenetics, as expected
(Table 2). The karyotypes of the 11 previously published cell lines
were essentially identical to those reported elsewhere [15,16].
Four cell lines (BLLAL, OKU, SALINA, BLMer) have been
karyotyped for the first time in the present paper. The BLMer cell
line was established from a recurrent tumor (case 29124).
Karyotype analysis of BLMer showed the same anomalies as
observed in the parental tumor (data not shown). Although cell lines
cannot fully recapitulate all the biological aspects of tumors [11],
the chromosomal alterations observed in cell lines are represen-
tative of their parent histology [17].
Figure 1. Correlation karyotype-high resolution aCGH. A RHG-banded karyotype of Ly47 showing 2 normal chromosome 16 (arrow). B
Karyogramme of Ly47 cell line showing a gain of chromosome 16 (arrow). C FISH with whole painting of chromosome 16 confirmed aCGH result. The
additional piece of chromosome 16 was translocated at the long arm of chromosome 11. D RHG-banded karyotype of Ly91 showing an add(13)(p12)
which is presented in 20% of cells (arrow). E Karyogramme of Ly91 cell line showing a non segmented gain on 1q (arrow). F FISH with whole painting
of chromosome 1(red) and 13(green) allowed to identify the origin of the material translocated at 13p. Hence, the add(13) became a der
(13)t(1;13)(q32.1;p12).
doi:10.1371/journal.pone.0007089.g001
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number of CNA per sample was 6 versus 9 for cell lines (n=14),
showing the same order of magnitude.
Partial duplication of the PVT1 mi RNA locus: a role in BL?
In the BL 84 and Ly 47 cell lines, the der(8)t(8;22) was totally
and partially duplicated respectively. This allowed the high-
resolution mapping of the translocation. The MYC 39 breakpoints
were mapped to the PVT1 locus that harbors mir1204, mir1205,
mir1206 and mir1207 [18]. Among these genes, only mir1204 and
mir1205 were duplicated in the two cell lines (Fig. 4). The
localization of these micro-RNAs in the 8q24 region raises
questions. Are these micro-RNA implicated in lymphomagenesis.
Are BL variant translocations a distinct group?
CNAs and CNVs in BL
A total of 145 CNA #2 Mb were detected. Among them, there
were 81 CNA mapped to Mendelian CNV. GSTT1 was the most
polymorphic gene in our set. GSTT1 is a member of a multigenic
family of detoxifying enzymes [19]. Four classes of isoenzymes
have been linked to human malignancy: GSTM, GSTP, GSTA
and GSTT. Several studies have shown that individuals who
harbor GSTM1
2/2 or GSTT1
2/2 as well as GSTP1 variants are at
an increased risk for a series of tumors [19,20]. Further studies are
required to clarify its role in Burkitt’s lymphoma.
CNV are not totally neutral variants. Many recent studies have
directly and indirectly implicated some Mendelian CNV in
genomic disorders [21,22]. A 560 Kb low-level amplification of
the 2p23 region was found in the BL Mer cell line and its parental
tumor, and confirmed by FISH (Figure 3 I, J). This region harbors
only BIRC6 gene which encodes an inhibitor of apoptosis and a
chimeric E2/E3 ubiquitin ligase [23]. However, the 3 copies on
chromosome 2 and the single copy on the other chromosome have
the same boundaries as a reported CNV. Interestingly, germline
amplification of BIRC6 was found in patients with a family history
of pancreatic cancer [24].
Somatic CNVs mapped to the immunoglobulin locus [25,26]
were the second type found in our study. BLs have clonally
Figure 2. Immunoglobulin Somatic Copy Number Variation. The immunoglobulin loci at chromosomal subbands 2p11.2 (IGK), 14q32.3 (IGH)
and 22q11.2 (IGL) showed acquired monoclonal alterations by the 244 K aCGH platform. The segmented rearrangements were identified by a stained
rectangle and the individual oligonucleotides are identified by a bold dot. The Y axis is the chromosomal position, the X axis is the ratio (loss is to the
left). A to D, S1: The IGH locus was rearranged in all cell lines (14/15) on the two chromosomes, with a specific pattern for each cell line. BL2 and BL31
have a t(8;14). A to D, S1: IGK gene rearrangements were detected in all cell lines and 8 have a clear biallelic rearrangement including LY91 the only
t(2;8). A to D, S1: IGL loci somatic rearrangements were observed in only 10 cell lines (7 biallelics) including four cases of t(8;22) as in BLAL. Other cell
lines are presented as supporting figures.
doi:10.1371/journal.pone.0007089.g002
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rearrangements can be detected by the 244 K aCGH platform
that showed a high sensitivity between the oligonucleotide arrays
[27]. The rearranged pattern is highly specific of each individual
malignant cell line confirming that they are monoclonal
proliferations. Several oligonucleotides have an intermediate value
between one and two copy losses (Figure 2, Figure S1, Figure S2,
Figure S3, Figure S4, Figure S5, Figure S6, Figure S7, Figure S8,
Figure S9, Figure S10, Figure S11). This could be related to
further rearrangements of IG genes in subclones. According to the
genetic model of lymphomagenesis, the frozen differentiation stage
might reflect the cell type in which the primary translocation
t(8;14) took place leading to maturation arrest. An alternative
hypothesis is that mature aggressive B-NHL originate from cells
with stem-cell features or that stemness was acquired during
lymphomagenesis by epigenetic remodeling [28].
Table 3. Minimal critical regions issued from tumor and cell lines.
Cytogenetic band position (Mb) Size (Mb) Gain/Loss Cell lines Tumors Cancer-related genes in the region miRNA
1q21.1q25.2 142,87–177 34,13 G 8 3 .300 genes, BCL9 PIAS3 BCA2 LHX4
1q32.1 200,97–201,36 0,39 G 3 0 MDM4 PIK3C2B LRRN5
PLEKHA6 PPP1R15B
1q44 240,24–241,35 1,11 G 4 0 ADSS HNRPU AKT3 ZNF238
C1orf121 FAM36A C1orf100
C1orf101 LOC440742
2p16.1 60,96–61 0,04 AMP 2 1 REL
3p14.2 60,43–60,53 0,1 L 4 1 FHIT
4p15.3p15.2 18,2–23,74 5,54 L 3 1 SLIT2 PPARGC1A GBA3 KCNIP4
MGC29898 GPR125
4q34.1 174,14–174,94 0,8 L 2 1 HMGB2 SAP30 HAND2 MORF4
SCRG1 GALNT7 GALNT17
4q34.3q35.1 182,3–186,69 4,39 L 3 1 SLC25A4 CASP3 DCTD ACSL1
ING2 IRF2 CARF LRP2BP STOX2
FLJ12716 MLF1IP WWC2 SNX25
ENPP6 FLJ30277 RWDD4A
FLJ33167 ANKRD37 HELT
6p24p22.4 11,2–26,4 15,2 L 3 0 .60 genes BMP6 FOXC1 IRF4
MAK SSR1 TFAP2A RIPK1
PRPF4B EEF1E1 NRN1 EXOC2
WRNIP1 RIOK1 HUS1B CAGE1
6q24.1qter 142,16–170,83 28,67 L 2 0 135 genes, PDCD2
7q21.1qter 87,24–158,6 71,36 G 5 1 444 genes
8q24.2 128,71–128,95 0,24 G 3 1 MYC mir-1204
9p21.3 21,89–22,31 0,42 L 2 2 CDKN2A/CDKN2B
11pterp13 pter-32,41 32,41 L 1 1 235 genes, FANCF,PLEKHA7
11q23.1 110,62–110,81 0,19 G 1 1 POU2AF1 C11orf53 FLJ45803
13q31.3q32.1 89,58–96,81 7,23 AMP 5 2 GPC5 DCT DNAJC3 CLDN10 mir-622 mir-17
GPC6 ABCC4 SOX21 DZIP1 TGDS mir-18a mir-19a
UGCGL2 GPR180 HS6ST3 mir-20a mir-19b-1
mir-92-1
13q32.2 97,79–97,85 0,06 G 4 2 FARP1
13q33.1q34 103,64–112,61 9,3 L 0 3 ING1 COL4A2 COL4A1 RAB20 LIG4
TNFSF13B EFNB2 ERCC5 FGF14
PCCA SLC10A2 IRS2 ARHGEF7
TNFSF13B ANKRD10
14q12q21.3 26,52–43,84 17,32 L 1 1 44 genes, FANCM mir-624
15q26.2qter 92,15–100,21 8,06 G 2 0 25 genes MCTP2, IGF1R, PCSK6
17pterp11.2 0–19,68 15,36 L 2 1 .200 genes TP53 mir-22 mir-132
mir-212 mir-195
mir-497 mir-324
doi:10.1371/journal.pone.0007089.t003
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In our study, the distribution of the CNA .2 Mb was bimodal,
with 6/12 primary tumors and 13/15 cell lines exhibiting
additional abnormalities to the IG/MYC translocation, in
accordance with the low number of chromosomal changes
previously reported [29,30]. A smaller group with partial
uniparental disomy resulting in loss of heterozygosity without
chromosomal imbalances besides classic chromosomal instability,
has been reported in BL [29].
Gains were more frequent at the following regions 1q (12/27),
13q (7/27), 7q (6/27), 8q (4/27), 2p (3/27), 11q (2/27) and 15q
(2/27). Ten MCRs were observed.
In BL, the most frequent additional anomaly is the duplication
of 1q [8,31].
MCRs on chromosome 1
Three MCRs were observed on 1q. The major one was
localized at 1q21.1q25.2 ,142.87–177.00.. In a recent study
using tiling-resolution aCGH, this MCR was larger and mapped
to 1q12q25.2 [31]. In the BL 41 cell line, the 1q21.1q21.3
,142.87–149.17. region harbored a 6 Mb amplicon (Fig. 3A, B,
C). In a recent study, a 1.35 Mb minimal deleted region ,143.65–
145.00., was associated with developmental defects [32]. This
region overlapped the BL41 amplicon, but the copy number peaks
(,142.87–143.28.) seemed to be different. The genomic
structure of 1q21 is extremely complex, with at least 4 large
segmental-duplication blocks ranging in size from 270 Kb to
2.2 Mb. Consequently, these duplicons favored the non-allelic
homologous recombination which might explain both the
congenital anomalies (Mefford et al., 2008) and malignancy,
particularly lymphoma. Although 1q rearrangements have no
impact on the prognosis of BL [9], amplification does nevertheless
contribute to tumor development [33]. BCA2 and PIAS3 that
mapped at the maximal amplitude of the BL 41 amplicon are thus
candidate driver genes in this amplicon. BCA2 has E3 ubiquitin
ligase activity and was found to be overexpressed in invasive breast
Figure 3. Various gained or amplified small regions description. A. Copy number profile of 1q21.1 amplicon in BL41:the 7 copies maximal
amplitude region was the ,142,87–143,28 Mb. interval that included BCA2 and PIAS3 genes. B and C. The amplifications of BCA2 and PIAS3 were
confirmed by FISH with BAC clones RP11-767O2 and RP11-74F4 respectively which showed a small HSR. D and E. In Namalwa a low level
amplification (4 to 5 copies) of 1q25.2 ,176,6–177. was confirmed by FISH with BAC clone RP11-175C8 which contains the LHX4 gene only. 3F. In
Namalwa the 13q31.33q2.1 ,89,58–95,82. region was amplified. The proximal part that harboured the polycistron mir-17 and a part of GPC5 gene
was present in 8 copies. The distal region, with maximal amplitude (12 copies), contained 12 genes including GPC5, GPC6 and ABCC4 (see text). G
and H. In BL 41 the REL gene was found amplified and FISH with BAC clone RP11-373L24 showed a small HSR. I and J Molecular cytogenetic on
BLMer cell line showing a duplication of BIRC6. RP11-121M15 BAC clone was choosen on the region of BIRC6. The latter gene was duplicated as
denoted by an arrow.
doi:10.1371/journal.pone.0007089.g003
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STAT3. PIAS3 signaling has been shown to prevent apoptosis and
enhance cellular proliferation through the regulation of genes such
as MYC [35]. Overactivation of STAT3 has been identified in
many cancers [36].
The second 1q MCR was 1q32.1 ,200.97–201.36..I t
encompasses MDM4. This gene has not been implicated in BL,
but MDM4 inhibits P53, and in vivo development of B-cell
lymphomas in Em-myc MDM4
+/2 mice is delayed compared to
that occurring in Em-myc MDM4
+/+ mice [37].
The third 1q MCRwas 1q44 ,240.24–241.35..I th a r b o r sAKT3
which is one of the 3 isoforms of AKT. The latter is a Ser/Thr kinase
in the PTEN/PI3K/AKT pathway and activation of AKT is often
observed in human cancers [38]. In primary hepatocellular
carcinoma, AKT3 was up-regulated as a result of a gained 1q44
region [39]. In the Namalwa cell line, a 0.4 Mb low-level
amplification (5 copies) at 1q25.2 ,176.6–177. containing 5 genes
was detected. Among them, LHX4, a LIM homeobox 4 was found to
be amplified by FISH (Fig. 3D+E). LHX4 is the partner of IGH in
t(1;14)(q25;q32) detected in pre-B acute lymphoblastic leukemia [40].
MCRs on other chromosomes
The second most gained arm was 13q. The major MCR was
13q31.3q32.1 ,89.58–96.81. containing a 6.24 Mb amplicon
,89.58–95.82. (Fig. 3F) as frequently seen in lymphomas but
also across a broad range of tumor types [41]. The proximal
segment of this amplicon contained microRNA-17 polycistron
[42,43] which was stably upregulated in the presence of
constitutive MYC expression [44]. The highest copy number
segment harbored 12 genes, including GPC5, GPC6 and ABCC4.
Glypican genes (GPC5 and GPC6), belong to a family of heparan
sulfate proteoglycans that are constantly expressed and up-
regulated in rhabdomyosarcoma with an amplified 13q31q32
region [45]. However, in case 29147 and in Namalwa cell line, the
DNA copy number of GPC5 argues against this gene as the driver
of the amplification. ABBC4 (MRP4), which encodes the multi-
drug resistance protein, could also play this role. It was present in
12 copies in the Namalwa cell line. It was found to be amplified in
several drug-resistant cell lines derived from various malignancies
[46]. ABBC4 transcripts were found upregulated in a set of BL with
gain of 13q31q32 region [30].
On chromosome 8, MYC was the only gene contained in a
240 Kb gained MCR at 8q24.2, originating either from t(8;14)
and t(8;22) rearrangements.
A 2p16 MCR contained a 40 Kb amplicon in BL 41. It
harbored REL (Fig. 3G, H), a member of the NF-kB family of
transcription factors, which was found to be amplified in primary
mediastinal B-cell lymphoma [47].
The 11q23.1 MCR mapped to ,110.62–110.81. contained
POU2AF1, a B-cell specific transcriptional coactivator which is
amplified in multiple myeloma [48].
A 1.8 Mb amplicon was found at 17p11.2, in the BL 41 cell line,
with a 381 Kb peak of 10 copies ,20.72–21.10. containing four
genes of mostly unknown function. The proximal and distal
boundaries of this amplicon with 7 copies, contained two kinases
genes, AKAP10 and MAP2K3. The genomic structure of 17p11 is
Figure 4. Virtual cloning of 8q24 region. MYC region breakpoints. In Seraphina, BL 84 and Ly 47 cell lines, MYC locus was gained. MYC region
breakpoints vary with primary anomalies. In BL 84 and Ly 47 cell lines with t(8;22), MYC breakpoints were mapped to PVT1(Huppi et al., 2008); mir-
1205 and mir1204 (not present on UCSC map, located on chr8:128877390-128877456) defined the MCR of this gain. In Seraphina, a 240 Kb
duplication was observed around MYCand located by FISH in the immediate vicinity this gene on the der(14)t(8;14) (data not shown). This duplication
contained hsa mir 1204.
doi:10.1371/journal.pone.0007089.g004
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totaling 183 Kb.
Gene loss regions in BL
The most frequent deleted arm was 3p in four cell lines and
one tumor, a rare finding in BL. A 100 Kb MCR localized at
3p14.2 ,60.43–60.53. contained the 5
th exon of FHIT (Fragile
Histidine Triad) (Fig. 5), a finding in agreement with earlier
studies [49].
On 9p, the 420 Kb MCR harbored CDKN2A/CDKN2B, a gene
rarely reported to be impaired in BL [50].
On 13q33.1q34 a 10 Mb MCR, detected only in three tumors,
harbored more than thirty genes. Among these ING1, COL4A2,
COL4A1, RAB20, LIG4, TNFSF13B, all in a small region, could
constitute the target of this loss. In case 29125 a single10 Mb deletion
at 13q14.1q14.3 removed the critical mir-16-1 and mir-15a involved
in CLL [42]. This rearrangement is not observed in the 15 cell lines.
On 17p, a large 19.86 Mb MCR had removed P53 as well as
several other genes. Mutations in the P53 gene have been found in
at least 33% of BL biopsy specimens [51] and in as much as 83%
of BL cell lines [52,53].
Some single deletions were observed. In case 28787, a deletion
at 2p23.1p16.3 particularly removed MSH2 and MSH6 genes that
do not seem to be frequently altered in lymphoma [54]. EBF1
(5q33.3 ,158.08–158.18.), the early B cell factor was lost in
Seraphina. In a recent work on ALL, mono-allelic deletions of
EBF1 were emphasized [55].
High resolution aCGH is a powerful method that allowed a fine
mapping of additional unbalanced chromosomal abnormalities in
BL, but karyotype still remain an essential tool to rapidly identify
balanced chromosomal translocations. A subgroup of BL without
CNAs, warrants further investigation (SNP array, whole genome
sequence) in order to find the necessary additional oncogenic events
to the MYC rearrangement [4]. The identification of the target
genes of the large MCR will need correlations with other genomics
data sets (gene expression, nucleotide sequence, epigenetic…) in
order to make the low throughput functional gene studies.
With regard to additional chromosomal abnormalities studied
by cytogenomics, BL appears to exhibit non-random genetic
heterogeneity as revealed by this study. The MCRs remain to be
fully functionally characterized in order to design targeted and
personalized therapies in poor prognosis disease [9].
Data Availability. The microarray data analyzed in this
paper have been submitted to the Array Express data repository
at the European Bioinformatics Institute (http://www.ebi.ac.uk/
arrayexpress/) under the following accession numbers: E-TABM-703.
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